Samarth Kulkarni

2021

In 2021, Samarth Kulkarni earned a total compensation of $17M as Chief Executive Officer at CRISPR Therapeutics AG, a 87% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$587,925
Option Awards$10,954,947
Salary$670,000
Stock Awards$4,819,680
Other$4,463
Total$17,037,015

Kulkarni received $11M in option awards, accounting for 64% of the total pay in 2021.

Kulkarni also received $587.9K in non-equity incentive plan, $670K in salary, $4.8M in stock awards and $4.5K in other compensation.

Rankings

In 2021, Samarth Kulkarni's compensation ranked 428th out of 12,412 executives tracked by ExecPay. In other words, Kulkarni earned more than 96.6% of executives.

ClassificationRankingPercentile
All
428
out of 12,412
97th
Division
Manufacturing
134
out of 5,498
98th
Major group
Chemicals And Allied Products
40
out of 2,374
98th
Industry group
Drugs
35
out of 2,095
98th
Industry
Biological Products, Except Diagnostic Substances
15
out of 452
97th
Source: SEC filing on April 25, 2022.

Kulkarni's colleagues

We found five more compensation records of executives who worked with Samarth Kulkarni at CRISPR Therapeutics AG in 2021.

2021

Brendan Smith

CRISPR Therapeutics AG

Chief Financial Officer

2021

Tony Ho

CRISPR Therapeutics AG

Former EVP, Research and Development

2021

Lawrence Klein

CRISPR Therapeutics AG

Chief Operating Officer

2021

James Kasinger

CRISPR Therapeutics AG

General Counsel

2021

Michael Tomsicek

CRISPR Therapeutics AG

Chief Financial Officer

News

In-depth

You may also like